Axsome Therapeutics, Inc.

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. The company operates in the United States with a portfolio of FDA-approved medications addressing major depressive disorder, excessive daytime sleepiness, and acute migraine treatment. Its commercial products include Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea patients, and Symbravo (meloxicam-rizatriptan) for acute migraine treatment.

Beyond its marketed products, Axsome maintains a pipeline of investigational compounds in various clinical stages. AXS-05 has completed Phase III testing for Alzheimer's disease agitation and Phase II evaluation for smoking cessation. The company is also developing AXS-12 (reboxetine) for narcolepsy, AXS-14 (esreboxetine) for fibromyalgia, and solriamfetol for attention deficit hyperactivity disorder and shift work disorder-related excessive sleepiness, among other indications. The company collaborates with Duke University on clinical research initiatives.

Axsome operates with approximately 925 full-time employees and is headquartered in New York, New York. The company is incorporated in Delaware and trades on Nasdaq.